Technical ArticlesCharacterization and Applications of a Newly Developed Rabbit Monoclonal Antibody to Cytokeratin 7 (CK7) for ImmunohistochemistryQi, Weimin MD, PhD; Chu, Joseph BS; Zhou, Ding BS; Tacha, David PhDAuthor Information Biocare Medical, LLC, Concord, CA Reprints: Weimin Qi, MD, PhD, Biocare Medical, 4040 Pike Lane, Concord, CA 94520 (e-mail: [email protected]). Received for publication September 4, 2008; accepted October 15, 2008 Characterization and Applications of a Newly Developed Rabbit Monoclonal Antibody to Cytokeratin 7 (CK7) for Immunohistochemistry: Erratum The authors of the article appearing on page 233 of the May issue of the journal, would like to extend the following acknowledgement to Dr David Ferguson and Dr Deb Van Eyck: “The authors wish to thank Dr David Ferguson and Dr Deb Van Eyck at Waukesha Hospital for providing us with the valuable stained slide for figure 3B.” This erratum is published in the October 2009 issue of the journal. REFERENCE Qi W, Chu J, Zhou D and Tacha D. Characterization and Applications of a Newly Developed Rabbit Monoclonal Antibody to Cytokeratin 7 (CK7) for Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2009; 17:233–238. Applied Immunohistochemistry & Molecular Morphology: May 2009 - Volume 17 - Issue 3 - p 233-238 doi: 10.1097/PAI.0b013e3181917af0 Buy Errata Metrics Abstract In this paper, we describe the development of a novel rabbit monoclonal cytokeratin 7 (CK7) antibody. CK7 is widely used in immunohistochemical tests that are commonly performed in histopathology laboratories. Rabbits were immunized with a peptide corresponding to C-terminus of CK7. Recombinant monoclonal antibodies were developed using proprietary technology. Antibodies were screened by enzyme-linked immunosorbent assay against CK7 peptide, and the specificity of the antibody was verified by Western blotting on Hela cell lysates and by immunohistochemical staining on formalin-fixed paraffin-embedded tissue sections. One clone, designated as BC1 was selected and tested on a variety of human tissues. Its reactivity was tested and compared with a well-characterized mouse monoclonal CK7 antibody OV-TL 12/30 on lung, breast, ovarian, and colon cancers, and on a variety of normal tissues. The staining patterns and specificity were concordant with mouse monoclonal OV-TL 12/30. The BC1 clone, however, showed superior staining to OV-TL 12/30 in terms of intensity and staining of debris. CK7 combined with CK20 or CDX2 and TTF1 is a common panel used in histopathology laboratories in discrimination between primary adenocarcinomas and metastatic lung adenocarcinomas from colonic origin. We then developed a 4-step double stain (multiplex) assay by combining CDX-2 with CK7 in an antibody cocktail and tested the efficacy on lung, breast, and colon cancers. Results showed that this novel antibody can be used as a single component and/or in combination with CDX2 and TTF1 in applications for diagnostic pathology. Errata The authors of the article that appears on page 233 of the May issue of the journal, would like to extend the following acknowledgment to Dr David Ferguson and Dr Deb Van Eyck: “The authors thank Dr David Ferguson and Dr Deb Van Eyck of Waukesha Hospital for providing us with the valuable stained slide for Figure 3B.” This error has been noted in the online version of the article, which is available at www.appliedimmunohist.com . Applied Immunohistochemistry & Molecular Morphology. 17(5):464, October 2009. Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis C: Erratum. The article appearing on page 686 of the August issue of the Journal of Clinical Gastroenterology had incorrect information. In table 2, the results for GT 1 CA and GT 1 AA SVR were reversed. GT 1 CA SVR should be 18% and GT 1 AA SVR should be 22%. This error has been noted in the online version of the article, which is available at www.jcge.com . Journal of Clinical Gastroenterology. 43(10):1010, November-December 2009. © 2009 Lippincott Williams & Wilkins, Inc.